Compare RCMT & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | FATE |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 125.6M |
| IPO Year | 1997 | 2013 |
| Metric | RCMT | FATE |
|---|---|---|
| Price | $27.50 | $1.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 60.1K | ★ 1.3M |
| Earning Date | 04-03-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 29.88 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $186,737,000.00 | $6,646,000.00 |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $15.29 | $0.86 |
| 52 Week High | $28.19 | $1.94 |
| Indicator | RCMT | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 82.25 | 47.67 |
| Support Level | $26.23 | $1.06 |
| Resistance Level | N/A | $1.30 |
| Average True Range (ATR) | 1.34 | 0.08 |
| MACD | 0.98 | 0.00 |
| Stochastic Oscillator | 96.68 | 53.70 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.